#1Baxter 2020 Annual Meeting of Stockholders May 5, 2020 治療の準備 戻る 201701.01 12:00 PM ヘルプ カセットビラにはめ込 みます。カセットのチューブ チューブガイドにはめ込み ET.#22020 Annual Meeting of Stockholders 88 888 Introductions and Meeting Procedures Baxter light 2020 Annual Meeting Proposals Baxter Overview 10 Voting Results Questions and Answers po Adjournment 2#3Baxter 2020 Annual Meeting of Stockholders May 5, 2020 治療の準備 戻る 201701.01 12:00 PM ヘルプ カセットビラにはめ込 みます。カセットのチューブ チューブガイドにはめ込み ET.#4Baxter's Board of Directors José (Joe) E. Almeida Thomas T. Stallkamp Thomas F. Chen Michael F. Mahoney Patricia B. Morrison Stephen N. Oesterle, M.D. Baxter John D. Forsyth Cathy R. Smith James R. Gavin III, M.D., Ph.D. Albert P.L.Stroucken Peter S. Hellman Amy A. Wendell All Directors up for reelection at the 2020 Annual Meeting 4#5Baxter's Senior Leadership Team Giuseppe Accogli SVP and President, Americas Laura Angelini GM, Renal Care Alex Blanco SVP, Global Supply Chain Officer Wil Boren President, Advanced Surgery Dennis Crowley SVP, Business Development & Licensing Stacey Eisen SVP, Global Communications David Ferguson, Ph.D. GM, Medication Delivery Cristiano Franzi SVP and President, Europe, Middle East, Africa Andrew (Andy) Frye SVP and President, Asia Pacific Baxter Heather Knight GM, U.S. Hospital Products Jacqueline (Jackie) Kunzler, Ph.D. SVP and Chief Quality Officer Karen Leets SVP and Treasurer Paul Martin SVP and Chief Information Officer Sean Martin SVP and General Counsel Jeanne Mason, Ph.D. SVP, Human Resources Ellen McIntosh SVP and Corporate Secretary Sumant Ramachandra, M.D., Ph.D. President, Pharmaceuticals, and SVP, Chief Science and Technology Officer Reaz Rasul GM, Acute Therapies Philippe Reale VP, Planning & Fulfillment David Roman VP, Strategy, Financial Planning and Analysis James (Jay) Saccaro EVP and Chief Financial Officer Cathy Skala VP, Business Transformation Office Brian Stevens SVP, Chief Accounting Officer and Controller Clare Trachtman VP, Investor Relations Jorge Vasseur GM, Clincal Nutrition LO 5#6Safe Harbor Statement This presentation includes forward-looking statements concerning Baxter's financial results, business development activities, capital structure, cost savings initiatives, R&D pipeline, including results of clinical trials and planned product launches. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: demand for and market acceptance of risks for new and existing products; product development risks; product quality or patient safety concerns; continuity, availability and pricing of acceptable raw materials and component supply; inability to create additional production capacity in a timely manner or the occurrence of other manufacturing or supply difficulties (including as a result of a natural disaster, public health crises and epidemics/pandemics, regulatory actions or otherwise); the impact of global economic conditions (including potential trade wars) and public health crises and epidemics, such as the novel strain of coronavirus (COVID-19), on us and our customers and suppliers, including foreign governments in countries in which we operate; breaches or failures of the company's information technology systems or products, including by cyberattack, unauthorized access or theft; the adequacy of the company's cash flows from operations (which may be negatively impacted by collectability concerns as a result of the COVID-19 pandemic or otherwise) and other sources of liquidity to meet its ongoing cash obligations and fund its investment program; loss of key employees or inability to identify and recruit new employees; future actions of regulatory bodies and other governmental authorities, including the FDA, the Department of Justice, the SEC, the New York Attorney General and foreign regulatory agencies, including the continued delay in lifting the warning letter at our Ahmedabad facility or proceedings related to the investigation related to foreign exchange gains and losses; the outcome of pending or future litigation, including the opioid litigation and litigation related to our internal investigation of foreign exchange gains and losses; the impacts of the material weakness identified as a result of the internal investigation and our remediation efforts, includ the risk that we may experience additional material weaknesses or other deficiencies; proposed regulatory changes of the U.S. Department of Health and Human Services in kidney health policy and reimbursement, which may substantially change the U.S. end stage renal disease market and demand for our peritoneal dialysis products, necessitating significant multi-year capital expenditures, which are difficult to estimate in advance; failures with respect to compliance programs; accurate identification of and execution on business development and R&D opportunities and realization of anticipated benefits (including the acquisitions of Cheetah Medical and Seprafilm Adhesion Barrier from Sanofi); future actions of third parties, including payers; U.S. healthcare reform and other global austerity measures; pricing, reimbursement, taxation and rebate policies of government agencies and private payers; the impact of competitive products and pricing, including generic competition, drug reimportation and disruptive technologies; fluctuations in foreign exchange and interest rates; the ability to enforce owned or in-licensed patents or the prevention or restriction of the manufacture, sale or use of products or technology affected by patents of third parties; global, trade and tax policies; any change in laws concerning the taxation of income (including current or future tax reform), including income earned outside the United States and potential taxes associated with the Base Erosion and Anti-Abuse Tax; actions taken by tax authorities in connection with ongoing tax audits; and other risks identified in Baxter's most recent filing on Form 10-K and other SEC filings, all of which are available on Baxter's website. Baxter does not undertake to update its forward-looking statements unless otherwise required by the federal securities laws. Baxter CO#7Baxter 2020 Annual Meeting of Stockholders May 5, 2020 治療の準備 戻る 201701.01 12:00 PM ヘルプ カセットビラにはめ込 みます。カセットのチューブ チューブガイドにはめ込み ET.#82020 Annual Meeting Proposals PROPOSAL 1 Election of Directors Baxter PROPOSAL 2 Advisory Vote to Approve Named Executive Officer Compensation PROPOSAL 3 Ratification of Appointment of Independent Registered Public Accounting Firm PROPOSAL 4 Independent Board Chairman PROPOSAL 5 Right to Act by Written Consent 8#9Baxter 2020 Annual Meeting of Stockholders May 5, 2020 治療の準備 戻る 201701.01 12:00 PM ヘルプ カセットビラにはめ込 みます。カセットのチューブ チューブガイドにはめ込み ET.#10Advancing our Mission Save and Sustain Lives Baxter Peles 74452 10#11Rising to the Challenge of COVID-19 Maximizing production of critical medical products to support increased patient care levels Protecting employee health and safety through enhanced infection control procedures Actively recruiting up to 2,000 additional permanent and temporary roles globally Donating $2M+ to date to global relief partners through The Baxter International Foundation Baxter BAXTER 11#12Baxter Profile: A Diversified Global Portfolio¹ 2019 Global Revenue Baxter $11.4B Americas EMEA Asia Pacific 54% 26% 20% ~$3.6B ~$2.2B Renal Care Amia ~$0.9B Pharmaceuticals ¹Sales and related figures represent FY 2019; Other sales represent ~$0.5B. Pybracherite in wa Advanced Surgery ~$0.9B Baxter Critical Care NaCl 0.9% 125 ~$2.8B Medication Delivery ~$0.5B m/hr K CUMP Clinical Nutrition Acute Therapies 12#13Full Year 2019 Financial Snapshot¹ Global Reported Sales Adjusted Operating Margin +5% Operational Growth² ~$11.4B ~$11.1B FY 2018 as restated Baxter +140 Basis Points 17.3% 18.7% FY 2018 FY 2019 as restated Adjusted Diluted Earnings per Share +14% $2.91 FY 2018 as restated $3.31 Free Cash Flow³ +4% $1.4B $1.4B FY 2019 FY 2019 ¹Non-GAAP financial metrics referenced in this slide include operational sales growth, adjusted operating margin, adjusted diluted EPS, and free cash flow. A reconciliation to comparable U.S. GAAP measures is available at www.baxter.com. 2FY 2019 operational sales growth excludes the impact of foreign currency of approximately 3% and U.S. cyclophosphamide competition of approximately 0%; U.S. GAAP sales growth for the period was approximately 2% compared to FY 2018. ³Operating cash flows from continuing operations of $2,110 million in 2019 and $2,017 million in 2018 offset by capital expenditures of $696 million in 2019 and $659 million in 2018. FY 2018 FY 2019 as restated 13#14ONEBAXTER FORCE MULTIPLIER TOP QUARTILE GOALS Patient safety and Quality Growth through innovation io Best place to work Industry leading performance ETHICS AND COMPLIANCE IN EVERYTHING WE DO Baxter MISSION SAVE AND SUSTAIN LIVES STRATEGY Strengthen our portfolio and extend our impact through transformative innovation that spans prevention to recovery CULTURE LEVERS Speed Courage Simplicity Collaboration#15S ARA 露 O Baxter Patient Safety and Quality: Our Top Priority Investing in quality systems and processes Improving key quality metrics Strengthening relationships with global regulators Six FDA warning letters resolved since 2014 Sole remaining open letter: Ahmedabad, India ● Imager.M2m AXIO 15#16Best Place to Work: Recognized for Excellence Baxter's inclusive culture and diverse workforce help advance our Mission and fuel innovation. Select recognition highlights: Forbes 2019 AMERICA'S BEST LARGE EMPLOYERS Baxter POWERED BY STATISTA MILITARY FRIENDLY M 2020 EMPLOYER DIVERSITY BEST PRACTICES TOP 10% INCLUSION INDEX COMPANY 2019 E BEST HUMAN PLACES TO WORK RIGHTS CAMPAIGN FOLADATION 2020 for LGBTQ Equality 100% CORPORATE EQUALITY INDEX Baxter drives sustainability throughout its operations, and supports increased access to care, disaster relief, and STEM education, among other efforts. Select recognition highlights: MEMBER OF Dow Jones Sustainability Indices SAM In collaboration with a RobecoSAM brand FTSE4Good JUST COMPANIES CR MAGAZINE MOST 100 BEST CORPORATE CITIZENS 2019 16